{
    "title": "109_hr4829",
    "content": "The Act titled \"Reducing Fraudulent and Imitation Drugs Act of 2006\" mandates the use of counterfeit-resistant technologies for prescription drugs. The Act mandates the use of RFID tagging technology, tamper-indicating technologies, and blister security packaging for prescription drugs to authenticate their pedigree and ensure inventory control, tracking, tracing, and verification of shipment and receipt. The Act mandates the use of technologies like RFID tagging, tamper-indicating, and blister security packaging for authenticating prescription drugs and ensuring privacy protection. The Secretary prohibits technologies from containing information that can identify healthcare practitioners or consumers, and from transmitting advertisements or off-label drug information. The Secretary also encourages manufacturers to incorporate recommended technologies into drug packaging. The Act requires the use of overt optically variable counterfeit-resistant technologies in prescription drug packaging, similar to those used in currency security. These technologies must be visible to the naked eye, manufactured in a secure environment, and include non-visible covert security features. Standards for packaging aim to make counterfeiting more difficult. The Act mandates the use of advanced technologies in prescription drug packaging to prevent counterfeiting. Manufacturers must incorporate these technologies into various elements of the packaging, including blister packs, labels, and bottles. Shipments must also include labels with these technologies for supply chain inspection. The Act requires advanced technologies in prescription drug packaging to prevent counterfeiting. Labels with these technologies must be included in shipments for supply chain inspection. Misbranded drugs violate packaging or labeling requirements under the Federal Food, Drug, and Cosmetic Act. The Secretary of Health and Human Services must publish the National Specified List of Susceptible Prescription Drugs within 180 days of the Act's enactment, consisting of at least 30 drugs most frequently counterfeited in the US. The list must be reviewed and revised annually through 2009, with no fewer than 30 drugs included. The Secretary must implement requirements for prescription drugs on the National Specified List within specified timelines, and for all prescription drugs by December 31, 2010. Authorized uses during a transitional period are allowed. The Secretary will mandate the use of specific technologies to verify prescription drug authenticity between two effective dates. The Act defines \"pedigree\" as the history of drug transactions excluding consumer information, and \"prescription drug\" as a drug under regulation. The term \"prescription drug\" refers to a drug regulated under section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act. The term \"Secretary\" refers to the Secretary of Health and Human Services."
}